SOURCE: Kerecis


May 11, 2016 10:43 ET

Kerecis Fish Skin Wound Treatment Finalist for the Wound Innovation Award

Award to Be Presented at the European Wound Management Association Annual Meeting May 12

BREMEN, GERMANY--(Marketwired - May 11, 2016) - Kerecis, the company using Omega3-rich fish skin to heal human wounds and tissue damage, is a finalist for the Innovation Award at the 26th European Wound Management Symposium (EWMA). About 6,000 medical professionals attend the annual EWMA Conference, which is the largest wound conference in the world.

Kerecis Omega3 is intact fish skin that is rich in naturally occurring Omega3 polyunsaturated fatty acids and is used to regenerate damaged human tissue. When grafted onto damaged human tissue, such as a diabetic ulcer, the acellular material recruits the body's cells from the wound perimeter. These cells are then incorporated into the fish skin, which is ultimately converted into functional, living tissue. The fish skin structure resembles the native structure of human skin.

Studies have shown that cells and stem cells proliferate faster in this structure than in other materials such amnion-membrane and other mammalian-sourced materials. The Kerecis product is available in several European countries, including Germany, Austria, Switzerland, Iceland, Sweden and the United Kingdom.

The five nominated companies will have 10 minutes each to present their technological innovations before a panel of top scientists in the field of wound care. The panelists will assess the presentations and determine the winner. The other nominated companies are Birken AG; Imbed Biosciences, Inc.; Inotec AMD, Ltd.; and Nutech Society for Laser Technology and Testing mbH. The CMC-EWMA Wound Care Innovation Award will be presented on May 12.

About Kerecis
Kerecis develops regenerative technologies based on fish skin and Omega3 polyunsaturated fatty acids.

The initial Kerecis product, Kerecis Omega3 Wound, has been approved by the FDA and European regulatory authorities for wound healing. The technology is patented in the United States and multiple other countries. The Kerecis wound-healing product has a Medicare "Q" code (Q4158), allowing it to be easily identified and processed by Medicare and private insurance companies.

Production takes place in the Kerecis manufacturing facilities in Iceland. For more information, visit Distributor inquiries are welcome.

Contact Information

  • Contact:
    Kay Paumier
    Communications Plus
    Email Contact